Who's Booked On?
Identify Antigens Driving Autoimmune Disease & Biomarkers of Tolerance, Explore Novel Delivery Systems, & Evaluate Clinical Trials for Efficacious & Durable Antigen-Specific Immune Tolerance Therapies
Welcome to the 8th Antigen-Specific Immune Tolerance Drug Development Summit
Advancing Curative Therapies for Autoimmune Diseases
Immune tolerance offers a transformative approach to autoimmune diseases treatment and holds the power to modify the course of disease progression and significantly improve the quality of life for patients.
For 7 years, the 8th Antigen-Specific Immune Tolerance Summit has been at the forefront of innovative and novel approaches to immunology and inflammation and facilitated the development of new industry connections, research partnerships and seed investment across the immune tolerance field.
In 2025, this highly anticipated meeting will delve further into the complex reality of inducing immune tolerance as the landscape evolves with Diamyd, Anokion, COUR and more being the custodians of rapidly progressing clinical tirals.
From antigen selection, to establishing biomarkers of tolerance to brand-new clinical readouts, join 120+ autoimmune, immunology and inflammation experts at this timely and comprehensive network to continue to drive the momentum in the field.
With new companies, new antigens, and new disease targets, you can’t miss this opportunity to capitalize on the wealth of opportunities in antigen-specific immune tolerance drug development and contribute to the transformation of autoimmune disease treatment.
Networking Opportunities
Speed Networking
Enjoy meaningful exchanges with 100+ industry experts from Pfizer, Lilly, AbbVie, Moderna and many more
8+ Hours of Networking
Offering ample time to dive into deeper discussions, ask questions and explore insights beyond the presentations
Poster Session
Connect with peers over a cup of tea or coffee while discovering innovative work from the ASIT community
Agenda Highlights Include:
Standardizing the definition and biomarkers of tolerance to inform clinical endpoints for specific disease studies and work towards measurable milestones of efficacy
Delving into antigen-selection for complex autoimmune diseases with multiple antigen drivers to expand the wheelhouse of diseases immune tolerizing strategies can target including celiac disease, Type 1 diabetes, IBD and more
Advancing durable and efficacious ASIT therapeutics through early-stage clinical trials and beyond
Catch the Latest Clinical Data from Leading Companies in the Field:
Tolerogenic CNP-104 Treatment Regulates Th17 Cells Thereby Slowing PBC Progression and Liver Stiffness
Adam Elhofy, Vice President – Research & Collaborations, COUR Pharmaceuticals
Updates on the Phase 3 Trial for an Antigen-Specific Immune Tolerance Therapy for Type 1 Diabetes
Anton Lindqvist, Chief Scientific Officer, Diamyd
Clinical Evidence of Immune Tolerance Induction: Examples from Celiac Disease and Multiple Sclerosis
Kristie Grebe, Chief Scientific Officer, Anokion
Lessons Learnt from Type 1 Diabetes: Tolerance Mechanisms and Biomarkers
Lauren Higdon, Director - Marker & Discovery Research, Immune Tolerance Network
World Class Speaker Faculty Incudes:
Companies Attending Include:
Testimonials:
“Exciting presentations with emerging clinical data.” – Eli Lily & Co
“An excellent opportunity to catch up on latest developments and advancements in the ASIT field, with most key players represented” – Toleranzia
“Great mixture of examples illustrating clinical development progress and emerging new technologies to induce immune tolerance” – Moderna
Partners:
Other Events in the Series:
